Open AccessShort-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial
Author(s) -
Jonathan Corren,
Sarbjit S. Saini,
Rémi Gag,
Mark H. Moss,
Gordon Sussman,
Joshua Jacobs,
Elizabeth Laws,
Elinore S Chung,
Tatiana Constant,
Yiping Sun,
Jennifer Maloney,
Jennifer D. Hamilton,
Marcella Ruddy,
Claire Q. Wang,
Meagan P. O’Brien
Publication year - 2021
Publication title -
journal of asthma and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.162
H-Index - 30
ISSN - 1178-6965
DOI - 10.2147/jaa.s318892
Subject(s) - dupilumab , medicine , clinical endpoint , randomized controlled trial , allergy , placebo , placebo controlled study , gastroenterology , immunology , double blind , asthma , pathology , alternative medicine
Subcutaneous immunotherapy (SCIT) has been proven as an effective therapy against some allergens for seasonal allergic rhinitis (SAR) patients unresponsive to intranasal corticosteroids and/or antihistamines but carries risk of systemic allergic reactions. Dupilumab blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation in multiple diseases.